A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

@inproceedings{Nakamichi2015AP1,
  title={A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors},
  author={Shinji Nakamichi and Hiroshi Nokihara and Noboru Yamamoto and Yasuhide Yamada and Kazunori Honda and Yosuke Tamura and Hiroshi Wakui and Tatsuya Sasaki and Wataru Yusa and Katsuki Fujino and Tomohide Tamura},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2015}
}
This phase 1 study aimed to assess the tolerability, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of lenvatinib capsules in Japanese patients with solid tumors when administered orally up to 24 mg on a once-daily (QD) continuous schedule. Patients were enrolled in one of the two sequential cohorts (20 or 24 mg) of lenvatinib on a 28-day cycle based on the conventional 3 + 3 dose escalation design. Adverse events (AEs) were graded using the Common Terminology… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC) [abstract

  • L Havel, J-S Lee, +13 authors HP Dave
  • J Clin Oncol 32:5s (suppl; abstr 8043)
  • 2014
1 Excerpt

: a clinical outcomes and biomarker assessment

  • I Vergote, M Teneriello, +13 authors RT Penson
  • Cancer
  • 2013

Similar Papers

Loading similar papers…